NEW YORK (GenomeWeb News) – Sigma-Aldrich and Sangamo BioSciences today announced an expansion of their licensing deal covering zinc finger DNA binding protein-modified cell lines.

Under the new pact, Sigma-Aldrich gains exclusive rights to develop and distribute the ZFP-modified cell lines for commercial production of protein pharmaceuticals. In addition, Sigma-Aldrich has rights to certain ZFP-engineered transgenic animals for commercial applications.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: Icelandic genome sequences, approach to increase CRISPR efficiency, and more.

Testing showing "genetic incompatibilities" have led thousands of couples in Saudi Arabia to call off their weddings, the BBC reports.

Decode Genetics' ability to tell Icelanders, even ones the company hasn't sequenced, about their disease risk brings up ethical questions.

Genetic analysis of Britain's King Richard III and modern descendants of his relatives indicate breaks in the male line.